Nanexa: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal - Emergers

With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa now has strong momentum behind it going into the ongoing SEK 121m rights issue. At an investor meeting at Nanexa’s premises in Uppsala, the company presented both a clearer plan for NEX-22, with an expected start of Phase 1 in Q1’24, as well as two paths forward depending on the level of capital they manage to raise. We continue to see a wide range of different outcomes for both the company’s own and partner projects, all of which point to high potential from today’s depressed levels.

Länk till analysen i sin helhet: https://www.emergers.se/nanexa_q/